8-K: Twist Bioscience Exceeds Q1 Revenue Guidance

Twist Bioscience reported preliminary first quarter fiscal 2026 revenue of $103.7 million, surpassing its own guidance and growing 17% year-over-year.

Summary

• Preliminary, unaudited revenue for Q1 fiscal 2026 (ended December 31, 2025) reached approximately $103.7 million (+/$0.2 million).
• This represents a 17% growth compared to the same period in fiscal 2025.
• Total revenue exceeded the company's guidance expectations of $100 million to $101 million.
• DNA Synthesis and Protein Solutions revenue grew 27% to approximately $51.1 million (+/$0.1 million).
• NGS Applications revenue reached approximately $52.6 million (+/$0.1 million), also ahead of guidance.
• Excluding one large NGS Applications customer transitioning their assay, NGS Applications revenue grew 18% year-over-year.

Sentiment

Score: 8

Explanation: The company reported preliminary revenue significantly above its own guidance, with strong year-over-year growth across key segments. Management expressed confidence in continued momentum, indicating a very positive start to the fiscal year despite the unaudited nature of the results.

Positives

• Total preliminary revenue of approximately $103.7 million exceeded the company's guidance of $100 million to $101 million.
• Strong overall revenue growth of 17% year-over-year.
• DNA Synthesis and Protein Solutions revenue showed robust growth of 27%.
• NGS Applications revenue also performed well, growing to $52.6 million and exceeding guidance expectations.
• Excluding a specific customer transition, NGS Applications revenue grew 18%, indicating underlying segment strength.
• Management anticipates continued momentum and reacceleration in the NGS segment in the fiscal second quarter.

Negatives

• The results are preliminary and unaudited, subject to change, and stockholders are cautioned not to place undue reliance on these estimates.
• One large NGS Applications customer is transitioning their assay from research to commercial, which impacted the reported NGS growth rate (though the underlying growth was still strong).

Risks

• Actual financial results for Q1 FY26 may differ materially from preliminary estimates due to completion of closing procedures and final adjustments.
• Inability to attract new customers and retain/grow sales from existing customers.
• Failure to achieve sufficient revenue to attain or maintain positive cash flow from operations or profitability.
• Risks associated with rapidly changing technologies and extensive competition in synthetic biology, potentially rendering products obsolete or non-competitive.
• Challenges in integrating and leveraging artificial intelligence and machine learning technologies.
• Limitations or difficulties in expanding DNA synthesis manufacturing capacity.
• Dependence on a single supplier for a critical component.
• Dependence on key personnel.
• Potential for additional regulations to increase costs and delay commercialization efforts.
• Impact of changes in U.S. trade policies and other trade actions, leading to increased costs and supply chain disruptions.
• Difficulties in maintaining and enforcing intellectual property protection.
• Uncertainty regarding economic and market conditions and the impact of adverse economic conditions.
• Challenges in obtaining necessary financing.

Future Outlook

Management expects continued momentum and reacceleration in the NGS segment moving into the fiscal second quarter. The company will issue its full financial results for the first quarter of fiscal 2026 on February 2, 2026.

Management Comments

• "We are starting the fiscal year strong with more than $103 million in revenue, growth of 17%, coming in ahead of our guidance of $100 to $101 million."
• "Were encouraged by our overall revenue growth as well as the momentum from DNA Synthesis and Protein Solutions and NGS Applications."
• "Excluding one large NGS Applications customer who is transitioning their assay from research to commercial, NGS Applications revenue grew 18% compared to same period of the year prior."
• "We see continued momentum and reacceleration of the NGS segment as expected moving into our fiscal second quarter."

Industry Context

Twist Bioscience operates in the synthetic biology sector, providing synthetic DNA tools for various fields including medicine, agriculture, industrial chemicals, and defense. Their silicon-based DNA Synthesis Platform aims to provide precision, scale, cost-effectiveness, rapid throughput, and high-quality tools, positioning them to accelerate customer efforts in developing solutions for better lives and sustainability. The strong preliminary revenue growth suggests robust demand within this innovative biotech segment.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: Positive impact due to better-than-expected preliminary revenue and strong growth, potentially leading to increased investor confidence and share price appreciation.
• Customers: Continued innovation and reliable supply of synthetic DNA tools, supporting their R&D and commercialization efforts.
• Employees: Positive outlook for company performance, potentially fostering job security and growth opportunities.

Next Steps

• Emily M. Leproust, CEO, will present at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026.
• The company will issue its full financial results for the first quarter of fiscal 2026 before the market opens on February 2, 2026.
• A conference call and live audio webcast for analysts and investors will be held on February 2, 2026, at 8:00 a.m. Eastern Time.

Key Dates

Recommendation

The preliminary Q1 FY26 revenue significantly exceeded the company's own guidance, demonstrating strong operational execution and market demand for Twist Bioscience's synthetic biology products. The 17% year-over-year growth, particularly the 27% growth in DNA Synthesis and Protein Solutions and the 18% underlying growth in NGS Applications, indicates robust momentum. While the results are unaudited, the substantial beat on guidance, coupled with management's positive outlook for continued reacceleration in the NGS segment, suggests a strong underlying business trajectory. This performance, especially in a competitive biotech landscape, warrants a "strong buy" recommendation for investors looking for growth in the synthetic biology space.

Keywords

Twist Bioscience, TWST, Preliminary Revenue, Q1 Fiscal 2026, DNA Synthesis, Protein Solutions, NGS Applications, Biotech, Synthetic Biology, Financial Results, Revenue Growth, Earnings Guidance